
EVH
Evolent Health, Inc.
0
Dormant
Evolent Health's rapid revenue growth sparks interest amid negative margins and dormant Decifer score.
The thesis
Evolent Health operates in healthcare information services with 46.9% revenue growth, despite a -24.1% net margin. The Decifer score is 2, indicating dormancy. Analyst consensus is BUY, contrasting with a -0.8x P/E ratio. Gross margin is 12.9%, suggesting operational challenges.
Why now
The recent 100-point Nasdaq gain and September ISM manufacturing PMI slip create a risk-off environment, making Evolent Health's growth story more compelling. The USA Unemployment Rate rose to 4.2% in September, potentially influencing healthcare spending.
What to watch
Evolent Health's next quarter revenue growth and margin expansion will be crucial in confirming its growth story. The company's ability to improve its gross margin above 12.9% will be a key indicator of operational improvement.
Key risks
Evolent Health's negative net margin and low gross margin pose execution risks. The company's DCF intrinsic value is negative at $-107, indicating valuation concerns. Macro risks include potential healthcare spending cuts amid rising unemployment.
Theme exposure
Healthcare, Biotech & Devices
DirectEvolent Health, Inc. operates in medical - healthcare information services. That places it inside the Healthcare, Biotech & Devices story.
This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.
A media publication. Not investment advice. Not a recommendation.